14,735 Shares in Abbott Laboratories $ABT Acquired by Runnymede Capital Advisors Inc.

Key Points

• Runnymede Capital Advisors bought a new position of 14,735 shares of Abbott (ABT) in Q4, valued at about $1.85 million and representing roughly 1.1% of the fund’s portfolio (its 26th largest holding).
• Analyst sentiment is mixed: several firms have trimmed price targets (Goldman to $121, RBC to $135) while Barclays raised its target to $144; MarketBeat shows a consensus rating of "Moderate Buy" with a consensus price target of $134.58.
• Abbott reported Q results with EPS $1.50 (in line) but revenue of $11.46B (below estimates), provided Q1 and FY2026 EPS guidance (1.120–1.180 and 5.550–5.800, respectively), and announced a quarterly dividend of $0.63 (2.4% yield; ex-dividend Apr 15, pay May 15).

Runnymede Capital Advisors Inc. purchased a new position in Abbott Laboratories (NYSE:ABT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 14,735 shares of the healthcare product maker's stock, valued at approximately $1,846,000. Abbott Laboratories accounts for approximately 1.1% of Runnymede Capital Advisors Inc.'s investment portfolio, making the stock its 26th largest position.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Capital International Investors lifted its position in shares of Abbott Laboratories by 2.5% in the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker's stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Abbott Laboratories by 5.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker's stock worth $2,022,080,000 after purchasing an additional 821,325 shares during the period. Invesco Ltd. lifted its position in shares of Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker's stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Abbott Laboratories by 3.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker's stock valued at $1,804,050,000 after acquiring an additional 499,351 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Abbott Laboratories by 7.2% in the 3rd quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker's stock valued at $1,727,869,000 after acquiring an additional 864,531 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays raised its price target on ABT to $144 and keeps an “overweight” view, a bullish signal that likely helped buying interest. Abbott Laboratories price target raised by Barclays
• Positive Sentiment: Coverage highlighting Abbott as a “dividend king on sale” (value/dividend investors) increases interest from income-focused buyers given its long track record of payout consistency. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Neutral Sentiment: Several sell‑side analysts remain constructive (maintaining buy/outperform ratings) but trimmed targets modestly (Evercore to $134 from $138; BTIG similar), which is mixed news — keeps analyst support but reduces implied upside. Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings
• Neutral Sentiment: Analysts and media note the stock’s recent underperformance versus the broader market even as it edges up intraday — an important context for short‑term momentum traders. Abbott Laboratories stock rises Wednesday, still underperforms market
• Negative Sentiment: Goldman Sachs cut its price target sharply to $121 from $140 (still a “buy”), a downgrade in expectation that can pressure sentiment and cap near‑term gains. Goldman Sachs adjusts price target on Abbott Laboratories to $121 from $140; maintains buy rating
• Negative Sentiment: Analyses flag recent share weakness (down materially over the past 1–3 months) and fading momentum; fundamental concerns include a modest revenue shortfall in the last quarter despite EPS in line and only modest FY guidance — reasons some investors remain cautious. Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness

Insider Buying and Selling

In related news, EVP Mary K. Moreland sold 613 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company's stock, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Eric Shroff sold 709 shares of the business's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,055 shares of company stock worth $353,097 in the last ninety days. Corporate insiders own 0.46% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Royal Bank Of Canada lowered their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an "outperform" rating for the company in a research note on Friday, January 23rd. The Goldman Sachs Group lowered their price objective on shares of Abbott Laboratories from $140.00 to $121.00 and set a "buy" rating for the company in a research note on Wednesday. Weiss Ratings lowered shares of Abbott Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, January 26th. Argus lowered their price objective on shares of Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Finally, Raymond James Financial decreased their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an "outperform" rating for the company in a research note on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $134.58.

Abbott Laboratories Stock Performance

NYSE ABT opened at $103.70 on Thursday. Abbott Laboratories has a 1 year low of $100.88 and a 1 year high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The firm has a market cap of $180.61 billion, a price-to-earnings ratio of 27.88, a PEG ratio of 1.64 and a beta of 0.79. The company has a fifty day moving average price of $109.17 and a 200-day moving average price of $120.35.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the business posted $1.34 EPS. The business's revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories's dividend payout ratio is presently 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.